Novel Efficient Multistage Lead Optimization Pipeline Experimentally Validated for DYRK1B Selective Inhibitors-Reference-Cited by-同舟云学术

Novel Efficient Multistage Lead Optimization Pipeline Experimentally Validated for DYRK1B Selective Inhibitors

Published:2022-10-14 Issue:20 Volume:65 Page:13784-13792
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Alexandrov Vadim¹,Vilenchik Maria²,Kantidze Omar³^ORCID,Tsutskiridze Nika³⁴,Kharchilava Daviti³⁴,Lhewa Pema⁵,Shishkin Aleksandr⁵,Gankin Yuriy³^ORCID,Kirpich Alexander⁵

Affiliation:

1. Liquid Algo LLC, Hopewell Junction, New York 12533, United States

2. Felicitex Therapeutics, Natick, Massachusetts 01760, United States

3. Quantori LLC, Cambridge, Massachusetts 02142, United States

4. Tbilisi State Medical University, Tbilisi 0186, Georgia

5. Department of Population Health Sciences, School of Public Health, Georgia State University, Atlanta, Georgia 30303, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.2c00988

Reference55 articles.

1. Principles of early drug discovery

2. Does In Vitro Potency Predict Clinically Efficacious Concentrations?

3. A wake‐up call to quiescent cancer cells – potential use ofDYRK1B inhibitors in cancer therapy

4. Mirk/Dyrk1B in cancer

5. Mirk/Dyrk1B Maintains the Viability of Quiescent Pancreatic Cancer Cells by Reducing Levels of Reactive Oxygen Species

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mirk/Dyrk1B Kinase Inhibitors in Targeted Cancer Therapy;Pharmaceutics;2024-04-11

2. Drug targets regulate systemic metabolism and provide new horizons to treat nonalcoholic steatohepatitis;Metabolism Open;2024-03

3. Structural perspective on the design of selective DYRK1B inhibitors;2022-12-23